key: cord-0702498-9kk718g7 authors: Estofolete, Cassia Fernanda; Fares, Gislaine Fusco; Banho, Cecilia Artico; Sacchetto, Livia; Campos, Guilherme R.F.; Moraes, Marília M.; dos Santos, Thayza M.I.L; da Silva, Gislaine C. Dutra; Queiroz, Flavia; Mendes, Lina de Moura; Salomão, Maria Lúcia Machado; Negri, Andreia Francesli; Barcelos, Michela Dias; Nogueira, Mauricio L. title: Predictors of death in COVID-19 vaccine breakthrough infections in Brazil date: 2022-02-02 journal: J Infect DOI: 10.1016/j.jinf.2022.01.040 sha: 73efeefa6a42e52b8d6f244f27ad1feea612c393 doc_id: 702498 cord_uid: 9kk718g7 nan Recently, Whitaker and coworkers reported in the Journal evidences of the COVID-19 vaccine effectiveness in most clinical risk groups, with care to highlight the heterogeneity of seropositivity after 1 or 2 doses in individuals with diabetes, chronic heart disease, chronic liver, severe asthma, morbid obesity, and especially immunosuppressed, in which they observed a reduced S-antibody response and vaccine effectiveness (1) . We read with interest the article, especially because we believe in impact of vaccination against COVID-19 in groups with comorbidities. Through a retrospective, cross-sectional study, based on data from the SIVEP-Gripe Database, the COVID-19 Immunization State Database, and the local medical reporting system, our analysis identified characteristics that may be associated with increased risk of death in vaccinates hospitalized with COVID-19 in a reference health care center. Our outcome of interest was COVID-19-related death in patients with SARS-CoV-2 infection confirmed by RT-PCR with signs/symptoms appearing 15 days or more after vaccine series completion, a period considered reasonable to establish immunity. Vaccine breakthrough infections are defined as the detection of SARS-CoV-2 RNA or antigen in a respiratory specimen collected from a person ≥14 days after they completed all recommended doses (2). Following these definitions, the patients were divided into two groups upon admission, confirmation of COVID-19 infection via RT-PCR and completed information about COVID-19 vaccination status: i) breakthrough infection and ii) unvaccinated. All variables were subjected to binary logistic regression to define variables that might predict the different clinical outcomes. To select the variables that would comprise the final model, discriminant analysis was performed with p<0.1, estimated by Rao's score test. The variables that obeyed the predefined criteria were subjected to multivariate analysis, with significance defined as p<0.05. All data were tabulated and analyzed with SPSS version 25 software (SPSS, Inc; Chicago, IL, USA). Between January 5 and September 12, 2021, 2,777 (68.5%) were enrolled ( Table 1 ). The unvaccinated patients were predominantly male (56.6%) with a mean age of 51.08 (±15.56) years, and 71.5% had one or more comorbidity. These findings are agreed with previous studies that described the clinical profile of patients hospitalized with COVID-19 since the beginning of pandemic, being the disease severity associated with risk factors such as male gender, advanced age, and the presence of comorbidities (3) (4) (5) (6) . In contrast, the vaccinated patients were an average of 73.64 (±12.21) years old, and 95.4% had comorbidities. Being statically higher in this (p<0.001, in both cases) ( Table 1) . Correlation between complete vaccination, comorbidities, and advanced age was expected according to the definition of priority groups for immunization, which focused on age and comorbidities. This consideration is crucial when analyzing data from vaccinated patients to avoid erroneous associations between vaccination status and hospitalization. The values for Spearman's correlation coefficient confirmed this observation once it was negatively correlated with complete vaccination series when controlling for age and comorbidities ( = -0.005; p=0.777). In our data analysis according to vaccine status to define death risk, the univariate analysis identified age > 60 years, presence of comorbidities, cardiopathy, liver disorder, diabetes, neurological disorder, immunocompromised status, pneumopathy, and kidney disease as predictors of death in unvaccinated patients. The discriminant analyses selected six variables (age > 60 years, female sex, liver disorder, kidney disease, obesity, immunocompromised status) that were statistically significant when subjected to multivariate analysis (Table 2) . Our data depict a second wave of the pandemic in which different variants of the virus were circulating in the country and concerns addressed the impact on younger adults. A change in age profile was observed particularly after the emergence of the P1 (Gamma) variant in Manaus, with higher mortality seen among hospitalized patients in the 20-59 age range compared to the first wave of COVID-19 (7). Our data correspond precisely to the circulation of the Gamma variant in the city and region and consequent overload of the local health system, as already reported (8). In contrast, the vaccinated patients in our study presented a different profile. While several comorbidities were important predictors of death in unvaccinated patients, in the vaccinated group only age >59 and the presence of kidney disorders were predictors of death in univariate analysis and remained in the multivariate analysis (Table 2 ). The impact of renal disease, in its various stages, on the formulation of effective immunity after immunization against COVID-19 has been investigated. As Once breakthrough infection is expected, it is essential to understand the profile of patients who require hospitalization even after complete COVID-19 vaccination for more effective management. In our sample, breakthrough infections associated with hospitalization and death were more frequent in older patients (age ≥60 years) and those with kidney disorders. Although this study is retrospective, it is based on a large dataset. Our propose is highlighting to individual characteristics that should be considered when caring for patients, in addition to signs and symptoms. Our findings demonstrate how COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups. J Infect. 2022. 2. CDC. COVID-19 vaccine breakthrough case investigation and reporting: National Center for Immunization and Respiratory Disease Risk factors for death in 1859 subjects with COVID-19 Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data This case report is dedicated to our fellow frontline colleagues still facing the challenges of COVID-19 response.